{"id":"W2049103239","doi":"10.1002/jso.21160","title":"Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665","year":2008,"lang":"en","type":"article","venue":"Journal of Surgical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":421,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; GiST; Imatinib mesylate; Clinical endpoint; Stromal tumor; Oncology; Neoadjuvant therapy; Prospective cohort study; Surgery; Adjuvant therapy; Internal medicine; Imatinib; Clinical trial; Chemotherapy; Stromal cell; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001327248,0.0003144875,0.001959031,0.0002975882,0.0001312776,0.000008513316,0.0001904792,0.00004363601,0.00005752559],"category_scores_gemma":[0.001033446,0.0002206657,0.0004717004,0.0001996224,0.0005696595,0.0001821879,0.000122574,0.0005821338,0.000001785191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002224178,"about_ca_system_score_gemma":0.001118442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000357666,"about_ca_topic_score_gemma":0.000004395064,"domain_scores_codex":[0.9959144,0.0002759895,0.002122724,0.0003239823,0.0007413356,0.0006215473],"domain_scores_gemma":[0.9954381,0.001242961,0.001466417,0.0002263427,0.0009725799,0.0006535903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.861461,0.0231172,0.001080429,0.0004436723,0.000465267,0.02225322,0.00034237,0.0000567941,0.03407914,0.0001643912,0.001022995,0.0555135],"study_design_scores_gemma":[0.4864718,0.4334264,0.002543388,0.0009656377,0.0004857375,0.06158998,0.0002103343,0.0004019025,0.006716078,0.0001403387,0.00684754,0.0002008842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952698,0.0006372642,0.000305957,0.001383424,0.0001637212,0.001177853,0.0001998554,0.00001044869,0.0008516851],"genre_scores_gemma":[0.9315143,0.0003914823,0.06754513,0.00002714704,0.0002056664,0.00003338757,0.00003386454,0.00002821841,0.0002207502],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4103092,"threshold_uncertainty_score":0.8998485,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05635592054638017,"score_gpt":0.3749986522691786,"score_spread":0.3186427317227984,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}